Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01527591 · ClinicalTrials.gov registry record · NA
Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)
A NA study of Infection in Solid Organ Transplant Recipients, sponsored by University of California, Los Angeles.
- Active
- Registry status
- NA
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT01527591: Active NA study of Infection in Solid Organ Transplant Recipients, sponsored by University of California, Los Angeles.
NCT01527591 is a NA study of Infection in Solid Organ Transplant Recipients that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 17 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01527591, a NA study of Infection in Solid Organ Transplant Recipients, is active but no longer recruiting, sponsored by University of California, Los Angeles.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and long-term immunogenicity of the 13-Valent Pneumococcal Conjugate vaccine in children who are solid organ transplant recipients.
Primary Outcome
Immunogenicity, functional antibody responses and sero-conversion will be evaluated by enzyme immunoassay (EIA) and opsonophagocytosis assay to a booster immunization with PCV13 vaccine in SOT-recipient children 12-59 months of age
Conditions Studied
Interventions
- BIOLOGICAL Pneumococcal Conjugate Vaccine 13 (PCV13)
Study Locations (1)
California
- UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-02-01 |
| Est. Completion | 2025-12-30 |
| Phase | NA |
What the registry record for NCT01527591 still lists
NCT01527591 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Infection in Solid Organ Transplant Recipients appearing as the primary indexed condition, and to 1 intervention - of which Pneumococcal Conjugate Vaccine 13 (PCV13) is the first listed.
NCT01527591 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01527591 about?
NCT01527591 is a clinical study titled "Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)". The purpose of this study is to determine the safety and long-term immunogenicity of the 13-Valent Pneumococcal Conjugate vaccine in children who are solid organ transplant recipients.
What is the current status of trial NCT01527591?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 17 participants. The study started on 2012-02-01. Estimated completion is 2025-12-30.
What conditions does trial NCT01527591 study?
This clinical trial studies the following conditions: Infection in Solid Organ Transplant Recipients.
What interventions are being tested in trial NCT01527591?
The interventions under investigation include: Pneumococcal Conjugate Vaccine 13 (PCV13) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01527591?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01527591 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infection in Solid Organ Transplant Recipients
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01527591's enrollment target sits among peer trials
17 1871st of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI